About US
Contact us
-
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—againAstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers. No2018/11/12
-
As Novartis' other cancer launches struggle, Lutathera gets off to flying startNovartis has stumbled with a couple of its recent cancer launches, namely the complicated CAR-T rollout for Kymriah and come-from-behind Kisqali debut. But not so with Lutathera. The drug,approvedin2018/11/12
-
Themis eyes phase 3 study for chikungunya vaccine after passing midstage testThere aren't any vaccines or treatments for the painful viral infection chikungunya, but with phase 2 results announced this week, Themis hopes it's one step closer to changing that. The vaccine,2018/11/9
-
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myelomaLess than five months after posting positive top-linedata, Bristol-Myers Squibb and AbbVie have scored a new combo win for Empliciti. Tuesday, the FDAgreenlightedthe multiple myeloma immunotherapy, i2018/11/9
-
Provention Bio to develop Amgen’s celiac disease candidateBiopharmaceutical company Provention Bio has agreed to further develop Amgen’s AMG 714 drug candidate for the treatment of gluten-free diet non-responsive celiac disease (NRCD). The companies signed2018/11/8
-
AstraZeneca to sell drug rights to Covis Pharma in $371m dealAstraZeneca has agreed to divest its rights for Alvesco (ciclesonide), Omnaris and Zetonna (ciclesonide) medicines to Swiss speciality pharmaceutical firm Covis Pharma in a deal valued up to $371m. T2018/11/8
-
Sementis and Enesi Pharma partner to develop needle-free vaccinesAustralian biotechnology firm Sementis has entered into a research and development (R&D) partnership with UK-based Enesi Pharma for the development of potential vaccine candidates to treat peanut2018/11/7
-
Scotland seeks answers on Brexit costs to NHSScotland First Minister Nicola Sturgeon has urged the UK government to provide answers on how much Brexit will cost the country’s National Health Service (NHS). WithBrexitless than six months away, c2018/11/7
-
Sanofi signs $1bn drug development deal with Denali TherapeuticsSanofi has entered a deal valued at more than $1bn with US-based Denali Therapeutics to advance potential drug candidates for the treatment of neurological and systemic inflammatory diseases. DNL7472018/11/6
-
Yuhan licences lung cancer asset to Janssen in $1.25bn dealSouth Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.2018/11/6